Clinical trial
An Open-label, Single-arm, Multi-center, Phase 2 Study to Evaluate SHR-1210 Combination With BP102 in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Whose PD-L1 Positive and EGFR/ALK Wild Type.
NCT03666728 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Single-arm, Multi-center, Phase 2 Study to Evaluate SHR-1210 Combination With BP102 in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Whose PD-L1 Positive and EGFR/ALK Wild Type.
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- November 30, 2018
- Completion date
- March 11, 2020
- Enrollment
- 5 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.